Abstract
Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic. Objective: To examine the results of a trial of aripiprazole administered to a 13-year-old Mexican-American girl during the course of NMS. Methods: Vital signs and laboratory values obtained before and during the aripiprazole trial were compared. Results: Aripiprazole administration resulted in a mild increase in tachycardia and brief worsening of serum creatinine kinase level, but did not significantly affect temperature, respiratory rate, or blood pressure. Conclusions: In this adolescent with NMS, aripiprazole treatment was associated with a mild worsening of symptoms.
Original language | English (US) |
---|---|
Pages (from-to) | 187-188 |
Number of pages | 2 |
Journal | International Journal of Adolescent Medicine and Health |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - 2005 |
Externally published | Yes |
Keywords
- Aripiprazole
- Atypical antipsychotics
- Neuroleptic Malignant Syndrome
- United States
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Public Health, Environmental and Occupational Health